Key result
Universal once-in-a-lifetime Lp(a) testing and structured lipid clinic referrals optimize cardiovascular risk prevention.
Why the study?
Integration of Lp(a) into routine clinical practice remains fragmented due to persistent uncertainties around when to measure it, how to interpret assays, and how to manage elevated levels without approved Lp(a)-lowering therapies. As targeted therapies advance through phase 3 trials, a pragmatic framework is needed to align primary care and lipid clinics.
Answers are grounded in this paper and cite their sources.
This perspective provides an actionable clinical framework and referral algorithm to align primary care and lipid clinics in measuring, interpreting, and managing elevated Lp(a) to optimize cardiovascular risk reduction and prepare for emerging targeted therapies.
Lipoprotein(a) [Lp(a)] is a major, independent determinant of atherosclerotic cardiovascular disease and calcific aortic valve disease, yet its integration into routine clinical practice remains fragmented. Persistent uncertainties regarding when to measure Lp(a), how to interpret assay results, and how to manage elevated Lp(a) levels in the absence of approved Lp(a)-lowering therapies continue to hinder its adoption. Meanwhile, targeted therapies, including antisense oligonucleotides, siRNA agents, and small molecules, are advancing through phase 3 trials and may soon provide evidence regarding the clinical impact of pharmacological reduction of Lp(a). This evolving landscape demands a transition from passive awareness to active implementation. Early identification of individuals with elevated Lp(a), transparent communication of its clinical implications, and structured referral pathways between general practitioners and lipid clinics for the optimization of cardiovascular prevention and preparation for future therapeutic options are crucial steps for bridging the existing Lp(a) gap. This perspective proposes a pragmatic framework for integrating Lp(a) into cardiovascular risk assessment and management across primary and specialist care, addressing operational challenges in measurement, interpretation, and treatment to support an actionable and coordinated Lp(a) clinical pathway. To this end, it formulates practical advice to orient Lp(a) management in primary care.
No takes yet. Share an insight, caveat, or question.
Bianconi et al. (2026) conducted a review in Elevated lipoprotein(a) [Lp(a)] and atherosclerotic cardiovascular disease risk. Coordinated Lp(a) testing, cardiovascular risk stratification, and primary care-to-lipid clinic referral pathway was evaluated. Integrating universal once-in-a-lifetime Lp(a) testing with structured primary care-to-lipid clinic referrals optimizes cardiovascular prevention.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: